Adolor Corp (NASDAQ NM) discover, develop and market proprietary pharmaceutical products for the treatment of pain and the side effects that are caused by current pain treatments. The Group is in the development stage. The Group has a portfolio of small molecule product candidates that are in various stages of development ranging from pre-clinical studies to Phase I through Phase III clinical trials. Its product candidate, alvimopan, also known as ADL 8-2698, is designed to selectively block the effects of narcotic analgesics on the gastrointestinal tract. It has obtained licenses from Kwang Dong Pharmaceutical Co Ltd and Santen Pharmaceutical Co Ltd of Japan to develop and market dermal formulations of ADL 2-1294 in South Korea and North Korea for dermal pain and ophthalmic pain respectively.
Advanced Magnetics Inc. (AMEX) Advanced Magnetics, Inc. is a developer of superparamagnetic iron oxide nanoparticles used in pharmaceutical products. As a leader in our field, we are dedicated to the development and commercialization of our proprietary nanoparticle technology for use in therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cardiovascular disease and cancer. For more information about us, please visit our website at
http://www.advancedmagnetics.com , the content of which is not part of this press release.
Advanced Photonix, Inc. (AMEX) develop and manufacture optoelectronic semiconductor based components, hybrid assemblies and other proprietary advanced solid state light and radiation detection devices. The Group designs and manufactures silicon-based electro-optical components, assemblies and design solutions for a global original equipment manufacturers (OEMs) customer base. The products include customer specific assemblies for fiber optic data and telecommunications, PIN photodetectors, photodetector hybrids, military and commercial aerospace products, custom optoelectronic assemblies and FILTRODE(R). The Group also supplies detectors for high reliability (Hi-Rel) applications, including military and commercial aerospace and other applications requiring Hi-Rel specifications.
ADVENTRX Pharmaceuticals (Amex: ANX) is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance.
Aeterna Laboratoires, Inc. (NasdaqNM: AELA ) With its wholly-owned subsidiary Zentaris GmbH, is a biopharmaceutical company with an extensive product portfolio, including 2 already marketed and several other products at early and late- stage development in endocrinology, oncology and infectious diseases. Cetrorelix (Cetrotide(r)) is sold in the U.S. and Europe to the in vitro fertilization market, and is in Phase II clinical trials for endometriosis, uterus myoma and enlarged prostate (BPH). Miltefosine (Impavido(r)) is sold for black fever and has successfully completed a Phase III trial in parasitic skin disease. Neovastat(r) is in a Phase III trial for non-small cell lung cancer. Several other clinical programs are underway with various potential development candidates, supported by a worldwide network of scientific and marketing partnerships. Furthermore, AEterna benefits from a discovery platform of 100,000 molecules which is generating promising new compounds.
Aethlon Medical, Inc. (OTCBB: AEMD) is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the Hemopurifier(TM) to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur.
Affymetrix Inc (Nasdaq:AFFX) Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip® technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with subsidiaries in Europe and Asia, as well as manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company has about 1,000 employees worldwide.
Akorn, Inc. (AMEX: AKN) Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals.
